| Ytd | -35.85% | |
| 1y | 10.47% |
| Open | 3.07 | Prev Close | 3.05 | Low | 2.98 | High | 3.15 | Mkt Cap | 19.33M |
| Vol | 16.87K | Avg Vol | 23.30K | EPS | -1.47 | P/E | -2.08 | Forward P/E | -0.72 |
| Beta | -0.23 | Short Ratio | 0.75 | Inst. Own | 9.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 3.25 | 200-d Avg | 4.18 | 1yr Est | 11.56 |
EVAX News
Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatm
COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi
The new data demonstrates the potential to improve control of acute infection, latency, and viral re
COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi
COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi
COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi
COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio
Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript
COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio
COPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio
COPENHAGEN, Denmark, April 27, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechB
COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechB
COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechB
Shares of Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report) have received a consensus rat
COPENHAGEN, Denmark, March 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechB
COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechB
Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report) has received a consensus recommendation
Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript
Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report) was the recipient of a significant grow
COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi
COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi
Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market ses
Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The
Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session.
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916.
On Wednesday, 179 companies reached new 52-week lows.
During Tuesday, 95 stocks hit new 52-week lows.
On Wednesday, 479 stocks made new 52-week lows.
On Wednesday, 116 companies set new 52-week lows.
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is estimated to report earnings for i